To date, translational studies in SCLC are mainly restricted to the RP mouse model, driven by conditional biallelic inactivation of the Rb1 and Trp53 tumor suppressor genes (Meuwissen et al. 2003), which are almost universally mutated across SCLC patients (George et al. 2015, 2024). The gene discussed is TP53; the disease is small cell lung carcinoma.